When Can a Board Redeem a Poison Pill?

A board of directors can redeem a poison pill (shareholder rights plan) under conditions specified in the plan’s governing document, typically requiring board approval and usually triggered by a completed change of control or consent from the triggering bidder, with redemption decisions subject to fiduciary-duty review by courts.

The contractual foundation

A poison pill is not a board decree; it is a shareholder rights plan, a contract between the company and a rights agent. The plan document specifies precisely when the board can redeem (cancel) the rights. This is crucial: the board cannot casually revoke the pill whenever it wishes. The plan document is the governing law, and redemption powers are constrained to what the document allows.

Most plans allow the board to redeem the rights at any time before they are triggered (before a bidder crosses the ownership threshold). Once triggered, redemption is typically restricted. If a bidder acquires 15% of shares and the pill “flips in,” the plan usually permits redemption only by vote of the board after the bidder has completed a merger or acquisition, or by agreement with the bidder (if the board negotiates a negotiated deal), or by a supermajority shareholder vote.

Board discretion before the trigger

Before a pill is triggered, the board has broad contractual authority to redeem it. This power exists precisely to preserve board flexibility: if a bidder approaches the company and begins accumulating shares, the board can kill the pill to allow a negotiated discussion or to accept an unsolicited offer. A board that believes a pill is no longer in shareholders’ interests—because the company’s stock has recovered, competitive threats have receded, or circumstances have changed—can redeem it by board resolution.

However, this discretion is not unlimited. If the board redeems a pill specifically to allow an unwanted bidder to acquire the company cheaply, courts may scrutinize the decision under fiduciary-duty law. The board must act in good faith and cannot use the pill (or its redemption) as a tool for entrenchment or to favor insiders.

Board discretion after the trigger

Once a pill is triggered—typically when a bidder crosses a 15% or 20% ownership threshold—the plan’s document usually strips the board of unilateral redemption power. Redemption after trigger typically requires:

1. Shareholder vote: A majority or supermajority of shareholders (often excluding the bidder) votes to redeem
2. Bidder agreement: The bidder consents in writing to redeem
3. Completion of acquisition: The pill is automatically redeemed once a merger closes
4. Passage of time: Some plans allow automatic expiration (e.g., six months after trigger)

This structure is by design: once a threat has materialized, the board cannot unilaterally remove the defense without shareholder or bidder consent. This prevents a management team from extinguishing the pill to accept a hostile bid that serves only insiders.

Fiduciary-duty constraints on redemption

The Delaware Supreme Court and other jurisdictions have held that pill adoption and use are subject to fiduciary review. The board must show that it acted defensively, not to entrench itself. If a board redeems a pill to allow a bidder to acquire the company at a depressed price—all while the board knows a higher bid is forthcoming—courts may void the redemption as a breach of fiduciary duty.

The landmark case of Revlon, Inc. v. MacAndrews & Forbes Holdings established that once a board has decided to sell the company (or is responding to an unsolicited bid that threatens a change of control), the board’s duty shifts from protecting the company’s long-term interests to maximizing shareholder value in the sale. Under this heightened “Revlon duty,” a board cannot use the pill to lock in a low price; it must explore higher bids and redemptive decisions must be transparent and well-documented.

Conversely, if a board redeems a pill to defeat a hostile bidder because the board believes the bidder’s price is inadequate and the company’s prospects are better pursued independently, that decision—if made with reasonable process and good faith—is more likely to withstand judicial scrutiny.

Practical redemption scenarios

Scenario 1: Negotiated deal. A bidder approaches the board with an acquisition offer. The board, interested in exploring it, redeems the pill to allow the bidder to accumulate shares beyond the trigger threshold and conduct detailed due diligence. The board can do this unilaterally before the pill is triggered; afterward, it would likely need the bidder’s written consent or a shareholder vote.

Scenario 2: Proxy fight. A shareholder activist launches a campaign to replace the board, arguing the pill hurts stock price. At the annual meeting, shareholders vote to redeem the pill. The board, having lost the vote, must redeem. (Some plans allow shareholders to redeem by majority vote even if the board opposes it.)

Scenario 3: Poison pill expiration. The plan document specifies that rights expire on a fixed date (e.g., five years after adoption). On that date, the pill expires automatically without board action—no redemption is required.

Scenario 4: Merger closing. A bidder acquires the company via a negotiated merger. At closing, the pill is automatically redeemed as part of the transaction’s closing mechanics, as specified in the plan document.

The broader fiduciary context

A board’s discretion to redeem a poison pill must be exercised with the same care and diligence as any other business decision. Delaware courts apply the business judgment rule, which presumes the board acted properly unless the plaintiff proves bad faith, gross negligence, or lack of good process. If a board can show it conducted a reasonable investigation, considered alternatives, and redeemed (or maintained) the pill as part of a deliberate strategy, courts typically defer to the decision.

However, if a board redeems a pill secretly, without disclosure to shareholders, or to benefit a particular shareholder or insider, courts will scrutinize the decision and may find a breach of duty.

Successor rights plans

A board that redeems an old pill can adopt a new one. This maneuver is sometimes used to replace an old pill that has become unpopular or to extend the life of a pill that was about to expire. Shareholders often view this with skepticism—a “pill roll” can look like entrenchment. But if the board can articulate a legitimate business reason (e.g., industry consolidation, a new strategic threat), the adoption is likely permitted, subject to disclosure and shareholder notification.

See also